TY - JOUR
T1 - Flavanol-rich lychee fruit extract substantially reduces progressive cognitive and molecular deficits in a triple-transgenic animal model of Alzheimer disease
AU - Chen, Xiao
AU - Xu, Benhong
AU - Nie, Luling
AU - He, Kaiwu
AU - Zhou, Li
AU - Huang, Xinfeng
AU - Spencer, Peter
AU - Yang, Xifei
AU - Liu, Jianjun
N1 - Publisher Copyright:
© 2019 Informa UK Limited, trading as Taylor & Francis Group.
PY - 2021
Y1 - 2021
N2 - Effective treatment to prevent or arrest the advance of Alzheimer disease (AD) has yet to be discovered. We investigated whether OligonolR, an FDA-approved flavanol-rich extract prepared from lychee fruit and green tea, exerted beneficial effects relevant to AD in a triple transgenic male mouse model of AD (3×Tg-AD). At 9 months of age, untreated 3×Tg-AD mice vs. wild-type (WT) controls displayed cognitive deficits in behavioral assays and, at 12 months, elevated levels of hippocampal amyloid beta-protein (Aβ), amyloid precursor protein (APP), tau phosphorylation, and pro-inflammatory cytokines. 3×Tg-AD mice given Oligonol showed fewer cognitive deficits and attenuated pathological indices at 12 months. Oligonol treatment of 3×Tg-AD mice modulated expression of some critical brain proteins that involve multiple pathways relevant to mitochondrial dysfunction, proteasomal failure, endoplasmic reticulum (ER) stress and synaptic impairment. Together, these results demonstrate that continuous Oligonol treatment attenuates AD-like pathology and cognitive impairment of 3×Tg-AD mice and set the stage for clinical trials of this flavanol-rich plant extract in patients with early AD.
AB - Effective treatment to prevent or arrest the advance of Alzheimer disease (AD) has yet to be discovered. We investigated whether OligonolR, an FDA-approved flavanol-rich extract prepared from lychee fruit and green tea, exerted beneficial effects relevant to AD in a triple transgenic male mouse model of AD (3×Tg-AD). At 9 months of age, untreated 3×Tg-AD mice vs. wild-type (WT) controls displayed cognitive deficits in behavioral assays and, at 12 months, elevated levels of hippocampal amyloid beta-protein (Aβ), amyloid precursor protein (APP), tau phosphorylation, and pro-inflammatory cytokines. 3×Tg-AD mice given Oligonol showed fewer cognitive deficits and attenuated pathological indices at 12 months. Oligonol treatment of 3×Tg-AD mice modulated expression of some critical brain proteins that involve multiple pathways relevant to mitochondrial dysfunction, proteasomal failure, endoplasmic reticulum (ER) stress and synaptic impairment. Together, these results demonstrate that continuous Oligonol treatment attenuates AD-like pathology and cognitive impairment of 3×Tg-AD mice and set the stage for clinical trials of this flavanol-rich plant extract in patients with early AD.
KW - Alzheimer’s disease
KW - Oligonol
KW - amyloid beta
KW - endoplasmic reticulum stress
KW - inflammatory cytokines
KW - mitochondrial dysfunction
KW - proteasomal failure
KW - synaptic loss
KW - tau phosphrolation
UR - http://www.scopus.com/inward/record.url?scp=85074025484&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85074025484&partnerID=8YFLogxK
U2 - 10.1080/1028415X.2019.1673527
DO - 10.1080/1028415X.2019.1673527
M3 - Article
C2 - 31603034
AN - SCOPUS:85074025484
SN - 1028-415X
VL - 24
SP - 720
EP - 734
JO - Nutritional Neuroscience
JF - Nutritional Neuroscience
IS - 9
ER -